Phenonet Inc.

Amyotrophic Lateral Sclerosis

Phenonet Inc. is focused on amyotrophic lateral sclerosis, with clinical research centered on the functional needs of people living with mild to moderate disease. Its trial activity is directed toward outcomes relevant to motor neuron degeneration and changes in daily functioning.

  • ALS functional assessment
  • Motor function preservation
  • Neurodegenerative disease care

The sponsor’s research interest in ALS places emphasis on clinically meaningful measures of progression and symptom impact within a neurology setting.

Neuromuscular and Neurodegenerative Disorders

The company’s clinical portfolio reflects a therapeutic interest in neuromuscular disease and broader neurodegenerative disorders, with attention to conditions that affect strength, mobility, and functional independence.

  • Neuromuscular impairment
  • Progressive weakness
  • Functional decline

This area aligns with research aimed at understanding treatment effects on disease-related functional changes in adults with progressive neurological illness.

Supportive and Adjuvant Therapeutic Development

Phenonet Inc. is also active in adjuvant therapy development, with interest in treatment approaches intended to complement existing care in ALS. The sponsor’s work includes evaluation of therapies designed to support overall disease management.

  • Adjunctive treatment strategies
  • Symptom-directed therapy
  • Disease management support

Its research focus includes therapeutic areas where added treatment options may help address the functional burden of progressive neurological disease.

Clinical Outcomes in Functional Neurology

The sponsor’s research landscape includes interest in clinical outcome assessment within functional neurology, using measures that capture changes in mobility, self-care, and overall neurological performance.

  • Patient function measurement
  • Neurological performance outcomes
  • Disease burden assessment

This reflects a therapeutic emphasis on tracking how interventions relate to everyday function in people affected by motor neuron disease.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study of Cromolyn Inhalation Treatment for Patients with Mild to Moderate Amyotrophic Lateral Sclerosis (ALS)

    Recruiting

    2 1
    Investigated drugs:
    Czechia Germany Poland Spain